Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: Is there any connection?

Pharmacy World and Science

Volumn 23, Issue 3, 2001, Pages 120-121

  Burrull Madero, M A ^a   Del Villar Ruiz, A ^b   Grau Cerrato, S ^b   Andreu Garcia, M ^c   Goday Arno, A ^d  

^a HOSPITAL DEL MAR   (Spain)

^b Servicio de Farmacia   (Spain)

^c Servicio de Enfermedades Digestivas   (Spain)

^d Servicio de Endocrinologia   (Argentina)

Author keywords

Diabetes; Fibrinolytic; Hemorrhage; Meckel's diverticulum; Metformin

Indexed keywords

METFORMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM HEMORRHAGE; DISEASE COURSE; DRUG WITHDRAWAL; FIBRINOLYSIS; FOLLOW UP; HUMAN; MALE; MECKEL DIVERTICULUM; OBESITY; TREATMENT OUTCOME;

ADULT; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MECKEL DIVERTICULUM; METFORMIN; OBESITY;

EID: 0034964185     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011218520590     Document Type: Article

References (6)

1. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34)
2. Obesity
3. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus
4. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects
5. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients
6. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and trigliceride levels in non-diabetic obese subjects